Education
About Us
Working with TipRanks
Follow Us
bioAffinity Technologies, Inc. (BIAF)
NASDAQ:BIAF
BIAF Stock Chart & Stats
$2.94
-$0.03(-2.64%)
At close: 4:00 PM EST
$2.94
-$0.03(-2.64%)
Day’s Range― - ―
52-Week Range$2.34 - $48.06
Previous CloseN/A
Volume17.91K
Average Volume (3M)5.91M
Market Cap
$13.23M
Enterprise Value$6.77M
Total Cash (Recent Filing)$802.84K
Total Debt (Recent Filing)$670.00K
Price to Earnings (P/E)―
Beta-2.68
Next Earnings
Nov 12, 2025EPS Estimate
-2.7Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-5.10
Shares Outstanding4,498,709
10 Day Avg. Volume6,249,809
30 Day Avg. Volume5,911,951
Financial Highlights & Ratios
PEG Ratio0.07
Price to Book (P/B)4.24
Price to Sales (P/S)1.18
P/FCF Ratio-1.50
Enterprise Value/Market Cap0.51
Enterprise Value/Revenue0.88
Enterprise Value/Gross Profit2.95
Enterprise Value/Ebitda-0.61
Forecast
1Y Price Target
$0.50Price Target Upside-82.99% Downside
Rating ConsensusHold
Number of Analyst Covering1
Bulls Say, Bears Say
Bulls Say
Commercialization StrategyCyPath testing was up year-over-year with record testing volume in both June and July 2025, reflecting an accelerated commercialization strategy and increased clinical adoption.
Market ExpansionThe company is selling tests in several other states through referrals and word-of-mouth even before a broader commercial rollout.
Bears Say
Financial PerformanceThe company's capital constraints remain a concern; therefore, analysts maintain a Hold rating as they believe the risk/reward is balanced.
Investment RecommendationThe inability to operate profitably and the need to raise additional capital gives analysts pause, leading to a recommendation not to purchase shares at this time.
Revenue And ProfitabilityAnalysts are lowering their 2025 and 2026 revenue estimates, and widening their 2025 and 2026 GAAP loss per share estimates.
bioAffinity Technologies, Inc. News
BIAF FAQ
What was bioAffinity Technologies, Inc.’s price range in the past 12 months?
bioAffinity Technologies, Inc. lowest stock price was $2.34 and its highest was $48.06 in the past 12 months.
What is bioAffinity Technologies, Inc.’s market cap?
bioAffinity Technologies, Inc.’s market cap is $13.23M.
When is bioAffinity Technologies, Inc.’s upcoming earnings report date?
bioAffinity Technologies, Inc.’s upcoming earnings report date is Nov 12, 2025 which is in 22 days.
How were bioAffinity Technologies, Inc.’s earnings last quarter?
bioAffinity Technologies, Inc. released its earnings results on Aug 14, 2025. The company reported -$5.1 earnings per share for the quarter, missing the consensus estimate of -$3 by -$2.1.
Is bioAffinity Technologies, Inc. overvalued?
According to Wall Street analysts bioAffinity Technologies, Inc.’s price is currently Overvalued.
Does bioAffinity Technologies, Inc. pay dividends?
bioAffinity Technologies, Inc. does not currently pay dividends.
What is bioAffinity Technologies, Inc.’s EPS estimate?
bioAffinity Technologies, Inc.’s EPS estimate is -2.7.
How many shares outstanding does bioAffinity Technologies, Inc. have?
bioAffinity Technologies, Inc. has 4,498,709 shares outstanding.
What happened to bioAffinity Technologies, Inc.’s price movement after its last earnings report?
bioAffinity Technologies, Inc. reported an EPS of -$5.1 in its last earnings report, missing expectations of -$3. Following the earnings report the stock price went down -8.81%.
Which hedge fund is a major shareholder of bioAffinity Technologies, Inc.?
Currently, no hedge funds are holding shares in BIAF
Company Description
bioAffinity Technologies, Inc.
bioAffinity Technologies, Inc., a biotechnology company, engages in developing non-invasive diagnostic tests and targeted cancer therapeutics. The company offers CyPath lung, a diagnostic test, for early detection of lung cancer. It also researches targeted therapies to treat cancer at the cellular level. The company was founded in 2014 and is based in San Antonio, Texas.
BIAF Stock 12 Month Forecast
Average Price Target
$0.50
▼(-82.99% Downside)
Technical Analysis
Trinity Biotech
―
Precipio
―
BioNano Genomics
―
Intelligent Bio Solutions
―
Mainz Biomed B.V.
―
Ownership Overview
35.26% Insiders
3.80% Mutual Funds
0.09% Other Institutional Investors
60.85% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---